In vivo Ebola virus infection leads to a strong innate response in circulating immune cells

Citation
Caballero, I. S., A. N. Honko, S. K. Gire, S. M. Winnicki, M. Melé, C. Gerhardinger, A. E. Lin, et al. 2016. "In vivo Ebola virus infection leads to a strong innate response in circulating immune cells." BMC Genomics 17 (1): 707. doi:10.1186/s12864-016-3060-0. http://dx.doi.org/10.1186/s12864-016-3060-0.

Published Version
doi:10.1186/s12864-016-3060-0

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:29407830

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
In vivo Ebola virus infection leads to a strong innate response in circulating immune cells

Ignacio S. Caballero, Anna N. Honko, Stephen K. Gire, Sarah M. Winnicki, Marta Melé, Chiara Gerhardinger, Aaron E. Lin, John L. Rinn, Pardis C. Sabeti, Lisa E. Hensley and John H. Connor

Abstract

Background: Ebola virus is the causative agent of a severe syndrome in humans with a fatality rate that can approach 90%. During infection, the host immune response is thought to become dysregulated, but the mechanisms through which this happens are not entirely understood. In this study, we analyze RNA sequencing data to determine the host response to Ebola virus infection in circulating immune cells.

Results: Approximately half of the 100 genes with the strongest early increases in expression were interferon-stimulated genes, such as ISG15, OAS1, IFIT2, HERC5, MX1 and DHX58. Other highly upregulated genes included cytokines CXCL11, CCL7, IL2RA, IL2R1, IL15RA, and CSF2RB, which have not been previously reported to change during Ebola virus infection. Comparing this response in two different models of exposure (intramuscular and aerosol) revealed a similar signature of infection. The strong innate response in the aerosol model was seen not only in circulating cells, but also in primary and secondary target tissues. Conversely, the innate immune response of vaccinated macaques was almost non-existent. This suggests that the innate response is a major aspect of the cellular response to Ebola virus infection in multiple tissues.

Conclusions: Ebola virus causes a severe infection in humans that is associated with high mortality. The host immune response to virus infection is thought to be an important aspect leading to severe pathology, but the components of this overactive response are not well characterized. Here, we analyzed how circulating immune cells respond to the virus and found that there is a strong innate response dependent on active virus replication. This finding is in stark contrast to in vitro evidence showing a suppression of innate immune signaling, and it suggests that the strong innate response we observe in infected animals may be an important contributor to pathogenesis.

Keywords: Ebola virus, Transcriptional response, Transcriptomics, Interferon-stimulated genes

Abbreviations: CPM, Counts per million; EBOV, Ebola virus; GEO, Gene expression omnibus; ISG, Interferon stimulated gene; LASV, Lassa virus; MARV, Marburg virus; PBMC, Peripheral blood mononuclear cells; PFU, Plaque-forming units; rhAPC, Recombinant human activated protein C; rNAPc2, Recombinant nematode anticoagulant protein c2; rVSV, Recombinant vesicular stomatitis virus with the ebola glycoprotein; VLP, Virus-like particle
Background

Ebola virus belongs to the family Filoviridae and is an envelope, non-segmented, negative-stranded RNA virus with filamentous virion morphology. Infection with Ebola virus causes Ebola Virus Disease, a disease associated with mortality rates between 25 and 90 % [1]. The earliest clinical symptoms are non-specific and flu-like, such as high fever, headache and myalgia [1–3]. During the large outbreak in West Africa (2014–present), the symptoms also included diarrhea and vomiting [2]. The late stage of disease is associated with immune cell imbalances such as neutrophilia and coagulation disorders like diffuse intravascular coagulopathy [4–6].

It has been postulated that survival following Ebola virus infection correlates with the ability of the host to mount an early and robust interferon response. In cultured human liver cells, the virus has been shown to block specific aspects of the innate immune response, preventing the expression of interferon-stimulated genes [7, 8]. Experiments in animal models, including mice [9, 10] and guinea pigs [11], have provided evidence that the suppression of interferon signaling is important for pathogenesis.

Previous studies of primates exposed to wild-type Ebola virus strains have suggested that there is a strong interferon-like transcription signal in circulating immune cells [12]. It has not yet been established whether interferon signaling is seen only in circulating immune cells or whether there is evidence for interferon-induced mRNA expression in infected tissues as well. It is also not well established whether this response is dependent on active virus replication. Several studies have reported that during infections caused by respiratory and hemorrhagic fever viruses, circulating immune cells undergo major gene regulatory changes that result in the upregulation of many innate immune system genes [13–16]. One of the most interesting aspects about this surge in transcriptional activity is that it constitutes an early measurable indicator of infection.

In the present study, we studied the transcriptional profile of circulating immune cells obtained from several different studies. We investigated the most robustly expressed genes that were observed in the peripheral blood mononuclear cells (PBMCs) of cynomolgus macaques following different routes of infection (aerosol and intramuscular), as well as following vaccination of the host. We further investigated whether genes highly-upregulated in PBMCs also showed changes in expression in tissues of infected animals. Our results suggest that interferon-signaling is an early and robust response to Ebola virus infection throughout the body.

Methods

Datasets

Macaque model of intramuscular exposure to Ebola virus

This RNA sequencing study used cynomolgus macaques divided in two groups: vaccinated and Ebola-naïve [17]. The vaccinated group received an intramuscular injection of recombinant Vesicular Stomatitis Virus with the Ebola glycoprotein (rVSV/EBOV-GP) and a lethal dose of EBOV strain Kikwit several days later. The Ebola-naïve group was treated with a non-protective dose of rVSV/MARV-GP and received the same lethal dose of EBOV administered to the vaccinated group several days later. Blood samples were taken at 0, 4 and 7 days post-infection (see Table 1). PBMCs were isolated from the 18 blood samples, and RNA sequencing was performed using the same methods specified in [18].

Macaque model of aerosol exposure to Ebola virus

This study used rhesus macaques exposed to EBOV via aerosol (between 7.43×10^2 and 2.74×10^2 plaque-forming units (PFU)) 12 PBMC samples were collected at 0, 3, 6 and 8 days post-infection (see Table 1 for details) [19]. 19 spleen samples were obtained at 0, 1, 3, 4, 5, 6, 7 and 8 dpi. 12 adrenal gland samples were obtained at 1, 3, 4, 6, 7 and 8 dpi. 8 axillary lymph node samples were obtained at 0, 1, 3, 4, 5 and 6 dpi. 11 brain samples were obtained at 1, 3, 4, 6 and 7 dpi. 4 liver samples were obtained at 0, 3, 5 and 8 dpi. 3 pancreas samples were obtained at 0, 4 and 8 dpi. RNA was extracted from PBMCs and the other tissues and sequenced [20, 21]. For tissue homogenates, RNA was extracted from TRIzol-inactivated samples using BCP:chloroform, and total RNA was depleted of small RNAs (<200 nt) with a mirVana miRNA Isolation Kit per manufacturer’s instructions (Thermo Fisher, Waltham MA). Subsequently, ribosomal RNA was depleted using complementary DNA oligos and RNase H. For PBMC samples, mRNA was enriched using the Dynabeads mRNA Purification Kit (Thermo Fisher) per protocol. For all samples, TrueSeq v2 (Illumina, San Diego CA) libraries were constructed as described previously [20, 22], multiplexed using custom adaptors [20], and sequenced on a HiSeq to obtain 2 × 100 bp paired-end reads. Reads were demultiplexed with a 0 mismatch tolerance, and cross-sample contamination was back-calculated from synthetic RNAs that were spiked in prior to library construction [22]. The PBMC samples referenced above, as well as 24 additional PBMC samples taken at 0, 1, 3, 4, 5, 6, 7 and 8 dpi (Table 1), were also quantified using microarrays according to the methods specified in [23].

Mouse model of exposure to Ebola virus

This study used BALB/c mice divided into two groups [9]. One group was inoculated intraperitoneally with
wild-type EBOV. The other group was inoculated with mouse-adapted EBOV. Spleen samples were collected and homogenized at 0, 12, 24, 48 and 72 h post-infection for both groups (see Table 1). RNA was extracted from the 29 spleen samples and Agilent microarray processing was performed as described in [9].

Macaque model of aerosol exposure to Lassa and Marburg virus
This study used cynomolgus macaques divided in two groups [24]. One group was exposed to LASV Josiah and the other to MARV Angola, both groups received 1000 PFU of virus via aerosol. RNA was extracted from 24 PBMC samples (see Table 1) and RNA sequencing was performed.

Fold change analysis of sequencing data
After the raw sequencing reads of each study were generated, they were trimmed and the adapters were removed using Trimmomatic [25]. The processed reads were aligned to the Macaca mulatta genome (Ensembl release 77) [26] using TopHat 2.0.11 [27] with default parameters (segment length of 25, allowing up to 2 segment mismatches). Gene counts were obtained using HTSeq [28] to count reads that aligned uniquely to each gene. Counts were normalized to compensate for differences in library size using the trimmed mean of M-values normalization method included in the edgeR BioConductor package [29].

A gene was deemed to show statistically significant changes in expression at a specific time after infection if the moderated \( t \)-test between the infected and pre-infection samples resulted in a \( p \)-value lower than 0.05 (after Benjamini-Hochberg correction), with an absolute fold change in expression greater or equal to 3, and an average number of reads across all samples greater than 4 counts per million (CPM). When calculating relative changes to the pre-infection samples, infected samples were not subtracted from their individual uninfected controls (since not every infected sample had a pre-infected control), but from an average of all the pre-infection samples. Statistical significance, however, was calculated using the individual pre-infection samples, not their average.

Fold change analysis of microarray data
Agilent two-color human gene expression microarrays were processed using limma [30]. Fold changes were obtained by calculating the log-ratio between the intensities of the red channel (corresponding to experimental

---

**Table 1** Summarizes the datasets described below

| Study                              | Ref. | Tissue | Group                  | Platform      | Num. animals | Num. samples | Timepoints (samples/timepoint)   |
|-----------------------------------|------|--------|------------------------|---------------|--------------|--------------|----------------------------------|
| Macaque model of intramuscular exposure to Ebola virus | [17] | PBMC   | rVSV/EBOV-GP (vaccinated) | RNAseq        | 9            | 9            | 0, 4, 7 dpi (n = 3)              |
|                                   |      |        | rVSV/MARV-GP (Ebola-naive) | RNAseq        | 9            | 9            | 0, 4, 7 dpi (n = 3)              |
| Macaque model of aerosol exposure to Ebola virus | [19] | PBMC   | EBOV                   | RNAseq        | 8            | 12           | 0 (n = 4), 1 (n = 2), 3 (n = 2), 6 (n = 2), 8 (n = 2) dpi |
|                                   |      |        |                        | Microarray    | 14\(^a\)     | 36\(^a\)     | 0 (n = 18), 1 (n = 2), 3 (n = 2), 4 (n = 4), 5 (n = 4), 6 (n = 2), 7 (n = 2), 8 (n = 2) dpi |
| Spleen                           |      |        |                        | RNAseq        | 19           | 19           | 0 (n = 2), 1 (n = 3), 3 (n = 3), 4 (n = 2), 5 (n = 2), 6 (n = 2), 7 (n = 3), 8 (n = 2) dpi |
| Adrenal gland                    |      |        |                        | RNAseq        | 12           | 12           | 1 (n = 2), 3 (n = 1), 4 (n = 2), 6 (n = 1), 7 (n = 3), 8 (n = 2) dpi |
| Lymph node                       |      |        |                        | RNAseq        | 6            | 6            | 0, 1, 3, 4, 5, 6 dpi (n = 1)     |
| Brain                            |      |        |                        | RNAseq        | 10           | 10           | 1, 3, 4, 6, 7 dpi (n = 2)        |
| Liver                            |      |        |                        | RNAseq        | 4            | 4            | 0, 3, 5, 8 dpi (n = 1)           |
| Pancreas                         |      |        |                        | RNAseq        | 3            | 3            | 0, 4, 8 dpi (n = 1)              |
| Mouse model of exposure to Ebola virus | [9]  | Spleen | WT-EBOV                | Microarray    | 15           | 15           | 0 (n = 2), 12 (n = 4), 24 (n = 3), 36 (n = 3), 48 (n = 3) hpi |
|                                   |      |        |                        | MA-EBOV       | 14           | 14           | 0 (n = 2), 12 (n = 3), 24 (n = 3), 36 (n = 3), 48 (n = 3) hpi |
| Macaque model of aerosol exposure to Lassa and Marburg virus | [24] | PBMC   | LASV                   | RNAseq        | 7            | 12           | 0 (n = 4), 3 (n = 4), 6 (n = 2), 10 (n = 2) dpi |
|                                   |      |        |                        |               | 9            | 12           | 0, 3, 5, 9 dpi (n = 3)           |

\(^a\) 8 of these animals (and 12 of these samples) correspond to the 8 animals (and 12 samples) that were quantified using RNA sequencing
samples) and the green channel (corresponding to Human Universal Reference RNA [31]). These were later background-corrected and normalized using the LOESS algorithm. Agilent one-color mouse gene expression microarrays were processed in a similar manner as the two-color arrays, but using the reported expression value for each probe instead of the log-ratio between the two channels. Benjamini-Hochberg was used to correct the false discovery rate of multiple testing.

**Results**

To examine the response of the circulating immune system of nonhuman primates infected with Ebola virus, we used sequencing data from PBMCs of cynomolgus macaques infected with Ebola virus via intramuscular injection. These included pre-infection samples and samples taken 4 and 7 days after infection, as described in [17, 18] (unless specified otherwise, results and figures discussed in this manuscript refer to this dataset). We were first interested in connecting the transcriptomic data to previously reported information about the host cytokine response to Ebola virus infection and to examine whether other cytokines showed evidence of being upregulated during infection.

**Cytokine responses during Ebola virus infection**

Previous studies have shown strong increases in cytokine protein levels in the serum of infected animals and humans [32–34]. In our analysis, we observe that a subset of these cytokines reported to be present in the serum also show transcriptional upregulations in PBMCs by 4 days post-infection (IL6, IL1B, IL1RN, CCL8, CXCL10) and by 7 days post-infection (CCL2, CCL3, CSF1, TNF, CXCL1, FAS and CXCL8). Figure 1a shows the average fold-change (log2) for each of these cytokines on the y-axis, as well as the time after infection when the samples were taken on the x-axis. These results suggest a biphasic immune response to infection. IL1B is the only cytokine with an unusual transcription pattern, peaking at day 4 and returning to pre-infection levels by day 7.

Additionally, we identified several cytokines that were not previously known to play a role during Ebola virus infection. Among these, some became upregulated during the early stage of infection (day 4) CCL7, CXCL11, IL1R1 (cytokine receptor) and IL15RA, and others became upregulated during the late stage of infection (day 7): IL2RA, CSF2RB and others (Fig. 1b).

The majority of cytokines during Ebola virus infection in vaccinated animals did not reach a 3-fold change in expression at 4 or 7 days post-infection. Three notable exceptions were CCL7, CXCL10 and CXCL11, which peaked (respectively) at 42.8, 35.5 and 6.6 times the level of expression at 7 days post-infection compared to the pre-infection levels. These genes mirrored the expression patterns seen in the Ebola-naïve animals, but at a lower magnitude (Fig. 2). For example, by 4 days post-infection the expression level of CXCL10 had gone up 7.1-fold in the Ebola-naïve group, but only 3.1-fold in the vaccinated group. By 7 dpi, these values were 92.6-fold in the Ebola-naïve group and 35.5-fold in the vaccinated group.

**A strong and sustained early host transcriptional response after Ebola virus infection contains many genes associated with the innate immune response**

We also analyzed the macaque intramuscular Ebola dataset to identify genes that underwent strong, statistically-
significant increases in expression between pre-infection and 4 days post-infection. The thresholds that we used were 8 or higher fold-change with at least 4 read counts per million, and an adjusted \( p \)-value of less than 0.05. We found 125 genes that met these requirements, 25 of which showed levels of expression that peaked at 4 days post-infection and decreased by 7 dpi. The levels of expression of the other 100 genes remained constant or increased between days 4 and 7. Of these, 33 genes are known to be responsive to innate immunity transcription factors such as IRF3, IRF7 and STAT1 (also known as interferon-stimulated genes, or ISGs) [35, 36] (Fig. 3a) and are herein referred to as canonical ISGs. Figure 3a shows the log2-fold change of these interferon-stimulated genes at 0, 4 and 7 days post-infection, highlighting a few representative examples (MX1, ISG15, OAS1, DHX58 (RIG-I), IFIT2, and HERC5). The other 47 strong and sustained genes show similar responses to the ISG group but they have not been previously identified as downstream effectors of the interferon response (Fig. 3b). This population includes several neutrophil-associated genes (OLFM4, CD177, SERPINB1, S100P, PTX3 and MMP8), suggesting that there is an accumulation of neutrophils in PBCMs during the course of infection.

The strong increase in canonical ISGs following Ebola virus infection led us to investigate if this strong interferon-like response was observed in other animal models of Ebola virus infection. To do this, we used the Ebola mouse model dataset to analyze the ISG response in mice that had been infected with wild type EBOV (which is non-pathogenic in mice) and mouse-adapted EBOV (which is pathogenic in mice) [9]. Interestingly, we found that a strong ISG response was apparent 3 days after infection in mice that were infected, irrespective of pathogenesis (Fig. 4).

We validated these results using expression data from two previous studies that infected rhesus macaques with Ebola virus (intramuscular injection) and treated them with an anticoagulant drug (recombinant human activated protein C (rhAPC), and recombinant nematode anticoagulant protein c2 (rNAPc2) [37, 38]). We found significant similarity for a majority of early response genes even though the expression data was quantified using microarrays. For example, in the rhAPC samples, the expression of IFIT2 increased 4 log2-fold and 7.4
log2-fold at 3 and 6 days post-infection, respectively; in
the rNAPc2 samples the increases were 4.6 log2-fold
and 6.9 log2-fold at 3 and 6 days post-infection, respect-
ively. Additionally, we were also able to confirm these
patterns in a previous study that quantified PBMC sam-
pleS from Ebola virus-infected macaques using microar-
rays [12]. In this dataset, for example, IFIT2 expression
increases 3.4 log2-fold 3 dpi and remains sustained
throughout infection. The fact that this multiple tran-
scriptomic studies agree on this observation provides
additional evidence that the innate immune signaling is
upregulated after infection.

The sustained transcription of early responsive genes is
not present in a non-productive infection

Given the repeated appearance of a type I interferon-like
signature following Ebola virus infection, we were inter-
ested in determining whether the appearance of an early
innate immune response following a hemorrhagic fever
virus infection was a response to the injection of a
negative strand RNA virus. To do this, we used the
intramuscular Ebola dataset to compare the innate im-
une response to Ebola virus in non-human primates
that had been previously vaccinated against Ebola virus
to those that had been immunized against a different
hemorrhagic fever virus and were therefore susceptible
to Ebola virus (Ebola-naive group) [17, 18]. Figure 5
shows the changes in expression of four ISGs that illus-
strate the overall differences in response between the two
animal cohorts. In the Ebola-naive group, for example,
SIGLEC1 undergoes a 5.72 log2-fold change 4 days post-
infection, while in the vaccinated group the change is
only 2.53 log2-fold change (Fig. 5a). By 7 days post-
infection the difference is even greater: 7.64 in the
Ebola-naive group, and 3.36 in the vaccinated group. A
similar trend was seen for RSAD2, MX1, IFIT3, and the
majority of genes making up the early transcriptional
response: vaccinated animals showed significantly lower
levels of expression than Ebola-naive animals. These
results argue that the strong interferon-like response is
the result of active virus dissemination, and is not a
non-specific response to the injection of viral material.

---

**Fig. 3** Host genes showing strong and sustained changes in expression early after Ebola virus infection. Each line represents the average fold-change in expression (log2, y-axis) of each gene at different times (x-axis) after Ebola virus infection. Panel **a** shows canonical interferon-stimulated genes while panel **b** shows other strong and sustained genes. A representative sample of genes is shown in black to illustrate the individual patterns of expression.

---

**Fig. 4** Expression of interferon stimulated genes in spleens of Ebola virus infected mice. Each line represents the average fold-change in expression (log2, y-axis) of each gene at different times (x-axis) after Ebola virus infection, for each of the conditions: uninfected control, non-pathogenic wild-type Ebola virus infection, and pathogenic mouse-adapted Ebola virus infection.
The early transcriptional response is common to multiple hemorrhagic fevers

The early host transcriptional response that we observed in these studies appeared to be similar to strong innate transcriptional responses observed in other hemorrhagic fevers [24]. To compare these responses, we used gene expression data from cynomolgus macaques exposed via aerosol to either Lassa virus [24, 39] or Marburg virus [24, 40], and found that the innate response to both infections is highly similar to that of Ebola virus infection. This is illustrated in Fig. 6, which shows the changes in expression of four canonical ISGs (MX1, ISG15, DHX58 and OAS1) during Ebola, Lassa, and Marburg virus infection. All four genes are significantly upregulated at the earliest infected timepoint, and they remain sustained throughout the late stage of disease. For example, MX1 goes up 4.7 log2-fold 3 days after Lassa infection, 4.1 log2-fold 3 days after Marburg infection, and 4.9 log2-fold 4 days after Ebola virus infection. By 6–7 days post-infection, the log2-fold changes are 6.1, 6, and 5.4, respectively. By 9–10 days post-infection, the expression of MX1 seems to decrease mildly in Lassa and Marburg infection, but it remains at very high levels compared to the pre-infection baseline. During Lassa infection, ISG15 and OAS1 undergo similar expression changes to those of MX1: a strong increase, followed by a slight decrease in expression. For Marburg and Ebola virus infection, the early levels of expression of these genes increase more rapidly than during Lassa infection, and this trend continues during the late stage of disease. These results support the hypothesis that the immune system responds to different viral infections via a common, early, sustained and strong innate immune response.

Different routes of infection lead to a similar early transcriptional response

To determine if the route of infection could alter the early transcriptional response to Ebola virus infection, we looked at gene expression data from a study that exposed macaques to Ebola virus via aerosol and we

Fig. 5 Ebola-naive and vaccinated responses to Ebola virus infection. Each line represents the average fold-change in expression (log2, y-axis) of MX1, RSAD2, SIGLEC1, and IFIT3 at different times (x-axis) after Ebola virus infection. Panel a shows genes from Ebola-naive macaques, and Panel b shows genes from vaccinated animals. Panels c and d show the fold-change of SIGLEC1 and RSAD2 in vaccinated and Ebola-naive macaques.
compared it to the intramuscular injection data. Figure 7 shows the expression of the top 20 genes (Additional file 1) that have the strongest changes 4 days post-infection in the intramuscular group (Fig. 7a), as well as the pattern of expression of those same genes under aerosol exposure (Fig. 7b). RNA sequencing was used to quantify the expression in the intramuscular group, while microarrays were used for the aerosol group. We find that both groups show a strong increase in expression starting at 3–4 days post-infection and increasing during the course of disease. The average log2 fold-change in the intramuscular group at 4 days post-infection is 6.05, and in the aerosol group at 3 days post-infection it is 2.17. Given that this difference in magnitude takes place at different days, it is not possible to determine if the aerosol model shows a delayed response without obtaining additional samples at these timepoints. By 6 days post-infection, the fold change in expression for both models is similar.

**The innate immune response takes place across most tissues**

We next used the list of genes that were strongly upregulated in PBMCs in the macaque intramuscular Ebola dataset (125 genes, Additional file 1) and looked at their expression in the macaque aerosol Ebola dataset. We found that 88% of the genes from the intramuscular list showed strong upregulation in the aerosol model (111 genes, Additional file 2). We also looked at the expression of these genes in the remaining tissues in the aerosol model and found that the early immune response is present across most tissues at varying magnitudes and expression rates. Figure 8 shows the average expression rate of these genes across each tissue type. PBMCs become transcriptionally activated at 6 days post-infection, and show the strongest activation compared to the remaining tissues at 7 days post-infection. Liver starts becoming transcriptionally activated 3 days post-infection and the average expression level continues to increase by 5 and 8 days post-infection. The gene expression response in the spleen begins to increase at day 3 and also increases to similar levels as in the liver. In the adrenal gland and the pancreas, the expression level increases at 4 days post-infection and remains activated until the end of the infection. The axillary lymph node is the last to become activated, starting around day 6. The brain shows the lowest levels of activation, with only a slight increase that begins on days 4–6.
Discussion

Our analysis of the transcriptomic response to Ebola virus infection highlights that there is a strong activation of innate immune response genes at early times post-infection, most of which are classified as interferon-stimulated genes. This finding is consistent with other analyses of host responses to different viral infections [14, 24, 41] and with an earlier report [12]. These findings highlight a strong contrast between in vitro studies of Ebola virus function. Previous studies have shown that Ebola virus infection in vitro blocks the expression of ISGs in liver cells [7, 8]. This interferon-antagonism is based on the ability of VP35 to block the activation of IRF3, which inhibits the expression of interferon beta and other ISGs. Mutation of VP35 in a manner that allows IRF3 signaling has been studied in mice [10] and guinea pigs [11] using a recombinant Ebola strain containing a single-point mutation in VP35 (R322A). This mutation reduced the virus's ability to replicate and to block interferon signaling in vitro; in vivo, this virus did not cause pathogenesis in these animal models. These studies are consistent with the hypothesis that Ebola virus causes a systemic inhibition of the interferon response [42].

A caveat of these earlier studies is that they did not measure the innate immune response in the animals during Ebola virus infection to determine if there was an observable change in interferon-induced signaling in the animal model as well. Our analysis found that mice infected with both pathogenic and non-pathogenic EBOV show a strong expression of interferon-stimulated genes in the spleen. The fact that strong interferon responses

---

**Fig. 7** Aerosol infection shows a delayed transcriptional response. Each line represents the average fold-change in expression (log2, y-axis) of one of 20 top genes at different times (x-axis) after Ebola virus infection. Panel a corresponds to intramuscular injection (quantified using RNA sequencing), and Panel b to aerosol exposure (quantified using microarrays). Panels c and d illustrate the delay observed in two individual genes (ISG15 and IFIT2) in the aerosol and intramuscular groups.
occur in mice infected with non-pathogenic WT-EBOV is perhaps not surprising, as the non-adapted virus would be expected to induce a strong innate immune response. That the same response was seen in pathogenic MA-EBOV infected mice argues that a robust innate immune response in the spleen is generated in response to both pathogenic and non-pathogenic EBOV infection in mice. It was reported that in the mouse model the WT-EBOV showed strongly attenuated and delayed growth, while the MA-EBOV showed strong growth [9], perhaps suggesting that the non-mouse adapted virus was suppressed by innate signaling while the pathogenic virus was not.

This observation that innate immune genes are upregulated in the mouse-model of EVD is consistent with earlier reports suggesting that primary cells exposed to Ebola virus strongly activate interferon-like signaling [43] and data showing that in NHP-infection interferon-like signaling is upregulated [12, 38]. Together, the findings from two different model systems imply that innate signaling is largely unimpeded during Ebola virus infection and would be observed in human disease as well. Either IRF3 is activated or interferon is expressed and released into the circulation leading to an early, and global innate response in vivo. Additional experiments are needed to determine why we detect a significant increase in the expression of interferon-stimulated genes at the early stages of Ebola virus infection. One explanation could be that infected cells stimulate uninfected neighboring cells to produce interferon through a currently unknown mechanism, and that this stimulates them to express ISGs and to continue spreading the interferon signal (Fig. 9a). Since we see viral titers and ISG expression increasing throughout infection, further studies are required to understand if the populations of cells that are expressing ISGs are different from the ones that are undergoing viral replication. Another hypothesis is that, in vivo, some cells may retain their ability to translocate IRF3 to the nucleus and to express interferon, perhaps due to a missing VP35 (Fig. 9b). This is consistent with earlier reports showing that there are early immune-associated transcriptional responses in primary target cells exposed to either Ebola virions or virus-like particles (VLPs) [44, 45].

One of the hallmarks of Ebola virus infection is dysregulated levels of circulating proinflammatory cytokines. We observed the levels of expression of previously reported cytokines such as IL6, and CXCL8 (IL8) increase between 4 and 7 days post-infection. We also found several cytokines, such as CCL7 and CXCL11 (I-TAC), that showed significant changes in expression but whose protein levels have not been previously observed during Ebola pathogenesis. CXCL10 (IP-10) and CXCL11 were two of the cytokines that were expressed in animals that succumb to infection. Interestingly, we saw a significant increase in expression in vaccinated macaques infected with Ebola virus. This suggests that they are part of a conserved response in both the pathogenic and non-pathogenic response to Ebola virus. Both cytokines are induced by interferon alpha (they are ISGs), share a
common receptor (CXCR3), and are thought to be involved in the recruitment of effector T cells and NK cells [46]. They are also known to be induced during the acute phase in other types of viral infections including dengue [47], influenza [48], hepatitis B and C [49, 50], Herpes simplex [51] and HIV-1 [52]. Upregulation of CXCL10 has also been associated with hemorrhagic manifestations in patients infected with Sudan virus [34]. Our observations suggest that these cytokines are part of a core innate immune response that is triggered in all animals exposed to Ebola virus, but that they are overexpressed in animals that will succumb to disease.

By comparing how different routes of infection affect the cellular circulating immune response in Ebola virus-infected primates, we observed that infection via an aerosol and via intramuscular injection resulted in similar patterns of gene expression. Previous studies have reported a delay in the aerosol model of exposure compared to the intramuscular model [53], but given that we do not have samples from both infections taken at identical early time points, we were not able to confirm this observation.

Conclusions
Infection with Ebola virus leads to early and robust interferon-like responses that take place before the appearance of virus in the blood. This response takes place not only on circulating immune cells, but throughout the majority of infected tissues. Our results extend earlier observations of a strong innate immune response and suggest the involvement of new cytokines in Ebola virus infection. Further analysis of the cells responsible for driving this response, and for producing the different cytokine signals, will be important to understand the ability of the virus to replicate virtually unchecked in many tissues—even when these tissues show a strong interferon-expression signal—and to identify which cells are undergoing an uncontrolled ISG response.

Additional files

Additional file 1: 125 strongly upregulated genes in PBMCs in the macaque intramuscular Ebola dataset. For each gene, we report the log fold-changes at 4 and 7 days post-infection, the corresponding adjusted p-values and its functional category. (XLSX 20 kb)

Additional file 2: 111 strongly upregulated genes in PBMCs in the macaque aerosol Ebola dataset. For each gene, we report the log fold-change at 6 days post-infection, the corresponding adjusted p-values and its functional category. (XLSX 14 kb)

Acknowledgements
We thank Lee Wetzler for helpful discussions regarding data interpretation.

Funding
This work was supported by contracts W81XWH 10-02-0008, 11-02-0130, and USAMRAA Biomarkers W81XWH-11-1-0141, and by a grant from the National Science Foundation No. DGE 1144152 (AEL). This project has been funded in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Grant Number U19AI110818 to the Broad Institute. Marta Melé Meseguer is a Gilead Fellow of the Life Sciences Research Foundation.

Availability of data and material
Macaque model of aerosol infection with Ebola virus: The microarray expression data is available in GEO under accession GSE68809.
Mouse model of exposure to Ebola virus: The microarray data is available in the University of Washington Virocom server: bit.ly/Cilloniz_2011_microarray. Macaque model of aerosol exposure to Lassa and Marburg virus: The sequencing data is available in the Sequence Read Archive under accession numbers PRJNA222891 (Lassa) and PRJNA222892 (Marburg).

Macaque model of intramuscular exposure to Ebola virus: The sequencing data is available in Gene Expression Omnibus (GEO) under accession GSE64438.

**Authors’ contributions**

Conceived and designed the experiments: IC, JC. Performed the experiments: AH, LH, PS. Wrote the paper: IC, JC. All authors read and approved the final manuscript.

**Competing interests**

The authors declare that they have no competing interests.

**Ethics approval and consent to participate**

Ethics not required. Ethics approval and consent to participate manuscript. AH, LH, PS. Wrote the paper: IC, JC. All authors read and approved the final manuscript.

**References**

1. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet. 2011;377:849–62.
2. WHO Ebola Response Team. Ebola virus disease in West Africa — the first 9 months of the epidemic and forward projections. New En J Med. 2014; 371:1481–95.
3. Wong G, Kobinger GP, Qiu Y. Characterization of host immune responses in Ebola virus infections. Expert Rev Clin Immunol. 2014;10:781–90.
4. Bradfute SB, Swanson PE, Smith MA, Watanabe E, McDunn JE, Hotchkiss RS, Bariborski S. Variants M and W and disease severity in infants with respiratory syncytial virus infection. BMC Genomics. 2014;15:960.
5. Kash J, Mühleberger E, Carter V. Global suppression of the host antiviral response by Ebola-and Marburgviruses: increased antagonism of the type I inflammatory response and metalloproteinase gene expression during lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A. 2013;110:1893–8.
6. Baraness FT, Green FR, Thomas MJ, Law GL, Prol SC, Engelmann F, Messouadou I, Marini A, Feldmann H, Kutsche MG. Next generation sequencing reveals a controlled immune response to Zaire Ebola virus challenge in cynomolgus macaques immunized with VSV/ZEBOV/gP-protected against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A. 2013;110:1893–8.
7. Tswenhauf NA, Mattix ME, Johnson JC, Robinson CG, Pratt WD, Cashman KA, Wahl-Jensen V, Terry C, Olinger GG, Hensley LE, Honko A, Patel K, Regev A, Levin JZ. Comparative analysis of RNA sequencing methods for degraded or low-input samples. Nat Methods. 2013;10:623–9.
8. Matransa CB, Andersen KG, Winnicki S, Busby MA, Gladden AD, Tewhey R, Stremlau M, Berlin A, Gire SK, England E, Mosen LM, Mikkelsen TS, Odia I, Ehsiane PE, Folarin O, Goba A, Kahn SH, Grant DS, Honko A, Hensley L, Hapli C, Haney RF, Malboeuf CM, Birren BW, Gneuve A, Levin JZ, Sabeti PC. Enhanced methods for unbiased deep sequencing of Lassa and Ebola RNA viruses from clinical and biological samples. Genome Biol. 2014;15:519.
9. Gire SK, Goba A, Andersen KG, Sealfon RGC, Park DJ, Kanneh L, Jalloh S, Momoh M, Fullah M, Dudas G, Wohl S, Moses LM, Yezzaki NL, Winnicki S, Srutza CB, Malboeuf CM, Qiu J, Gladden AD, Schaffer SF, Yang X, Jiang P-P, Nekou M, Colubi A, Colombres MR, Fainne M, Maqbool A, Gbakie M, Kamara FK, Tucker V, Konuva E, et al. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science. 2014; 345(6203):1366–72.
10. Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, Paragas J, Young HA, Fredeking TM, Rote WE, Vlasuk GP. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet. 2003;362:1953–8.
11. Caballero IS, Bonilla G, Yen JY, Connor JH. Diagnosing Lassa virus infection by tracking the antiviral response. BMC Bioinformatics. 2012;13 Suppl 18:A13.
12. Zaas AK, Chen M, Varkey J, Veldman T, Hero AO, Lucas J, Huang Y, Turner R, Gilbert A, Lambkin-Williams R, Øien NC, Nicholson B, Kingsmore S, Carin L, Woods CW, Ginsburg GS. Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans. Cell Host Microbe. 2009;6:207–17.
13. Zaas AK, Burke T, Chen M, McClain N, Nicholson B, Veldman T, Tsikl EL, Fowler V, Rivers EP, Otero R, Kingsmore SF, Voora D, Lucas J, Hero AO, Carin L, Woods CW, Ginsburg GS. A host-based RT-PCR gene expression signature to identify acute respiratory viral infection. Sci Transl Med. 2013;5:203ra126.
14. Caballero IS, Bonilla G, Yen JY, Connor JH. Diagnosing Lassa virus infection by tracking the antiviral response. BMC Bioinformatics. 2012;13 Suppl 18:A13.
15. Marini A, Engelmann F, Feldmann F, Heberth K, Shuupet W, Birning D, Scott DP, Geisbert TW, Kawaoka Y, Katzke MG, Feldmann H, Messouadou I. Antibodies are necessary for VSV/ZEBOV/gP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A. 2013;110:1893–8.
16. Prins KC, Delpeut S, Leung DW, Reynard D, Volchkova YA, Reid SP, Ramanan P, Cárdenas WB, Amarasinghe GK, Volchkov VE, Basler CF. Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus virulent in guinea pigs. J Virol. 2010;84:3004–15.
17. Rubins KH, Hensley LE, Wahl-Jensen V, Daddario DiCaprio KM, Young HA, Reed DS, Jahnring PB, Brown PD, Relman DA, Geisbert TW. The temporal program of peripheral blood gene expression in the response of nonhuman primates to Ebola hemorrhagic fever. Genome Biol. 2007;8R174.
18. Meijas A, Dindo B, Suarez NM, Garcia C, Suarez-Arrabal MC, Jardi T, Blankenship D, Jordan-Villeagas A, Andura MI, Xu Z, Banchereau J, Chausabel D, Ramlno O. Whole blood gene expression profiles to assess pathogenesis and disease severity in infants with symptomatic viral infection. PLoS Med. 2013;10:e1001549.
19. Zaas AK, Chen M, Varkey J, Veldman T, Hero AO, Lucas J, Huang Y, Turner R, Gilbert A, Lambkin-Williams R, Øien NC, Nicholson B, Kingsmore S, Carin L, Woods CW, Ginsburg GS. Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans. Cell Host Microbe. 2009;6:207–17.
20. Zaas AK, Burke T, Chen M, McClain N, Nicholson B, Veldman T, Tsikl EL, Fowler V, Rivers EP, Otero R, Kingsmore SF, Voora D, Lucas J, Hero AO, Carin L, Woods CW, Ginsburg GS. A host-based RT-PCR gene expression signature to identify acute respiratory viral infection. Sci Transl Med. 2013;5:203ra126.
21. Caballero IS, Bonilla G, Yen JY, Connor JH. Diagnosing Lassa virus infection by tracking the antiviral response. BMC Bioinformatics. 2012;13 Suppl 18:A13.
30. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:Article3.

31. Novaradovskaya N, Whitfield ML, Basehore LS, Novaradovsky A, Pesich R, Usary J, Karaca M, Wong WK, Apelriikova O, Fero M, Perou CM, Botstein D, Bitman J. Universal reference RNA as a standard for microarray experiments. BMC Genomics. 2004;5:20.

32. Wauquier N, Becquart P, Padilla C, Baize S, Leroy EM. Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl Trop Dis. 2010;4.

33. Ebihara H, Rocko B, Marzi A, Feldmann F, Haddock E, Brinning D, LaCasse RA, Gardiner D, Feldmann H. Host response dynamics following lethal infection of the sus macaques with Zaire ebolavirus. J Infect Dis. 2011;204 Suppl Suppl 3:S991–9.

34. McElroy A, Erickson B. Ebola hemorrhagic fever: novel biomarker correlates of clinical outcome. J Infect Dis. 2014;210(4):558–66.

35. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, Rice CM. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2011;472:481–5.

36. Uchiumi F, Miyazaki S, Tanuma S. The possible functions of duplicated ets (GGAA) motifs located near transcription start sites of various human genes. Cell Mol Life Sci. 2011;68:2039–51.

37. Hensley LE, Stevens EL, Yan SB, Geisbert JB, Macias WL, Larsen T, Daddario-Dicaprio KM, Cassell GH, Jahrling PB, Geisbert TW. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis. 2007;196 Suppl Suppl 2:S390–9.

38. Yen JY, Garamszegi S, Geisbert JB, Rubins KH, Geisbert TW, Honko A, Xia Y, Connor JH, Hensley LE. Therapeutics of Ebola hemorrhagic fever: whole-genome transcriptional analysis of successful disease mitigation. J Infect Dis. 2011;204 Suppl Suppl 3:S1043–52.

39. Malhotra S, Yen JY, Honko AN, Garamszegi S, Caballero IS, Johnson JC, Muckler EM, Trevfy JC, Hensley LE, Connor JH. Transcriptional profiling of the circulating immune response to Lassa virus in an aerosol model of exposure. PLoS Negl Trop Dis. 2013;7:e2171.

40. Connor JH, Yen J, Caballero IS, Garamszegi S, Malhotra S, Transcriptional profiling of the immune response to Marburg virus infection. J Virol. 2015;89:9865–74.

41. Fink J, Gu F, Ling L, Tolfvenstam T, Olaf F, Chin KC, Aw P, George J, Kuznetsov VA, Schreiber M, Vasudevan SG, Hibbers ML. Host gene expression profiling of dengue virus infection in cell lines and patients. PLoS Negl Trop Dis. 2007;1.

42. Messaoudi I, Amarasinghe GK, Basler CF. Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus. Nat Rev Microbiol. 2015;13:663–76.

43. Hensley LE, Young HA, Jahrling PB, Geisbert TW. Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumour necrosis factor receptor superfamily. Immunol Lett. 2002;80:169–79.

44. Wahl-Jensen V, Kurz S, Feldmann H, Buehler LK, Kindrachuk J, DeFilippis V, da Silva Correia J, Früh K, Kuhn JH, Burton DR, Feldmann H. Ebola virion attachment and entry into human macrophages profoundly effects early cellular gene expression. PLoS Negl Trop Dis. 2011;5:e1359.

45. Aytham N, Bradflute SB, Anthony SM, Statham KS, Bavari S, Bray M, Ozato K. Virus-like particles activate type I interferon pathways to facilitate post-exposure protection against Ebola virus infection. PLoS One. 2015;10:e0118345.

46. Groom JR, Luster AD. CXCRI ligands: redundant, collaborative and antagonistic functions. Immunol Cell Mol Life Sci. 2011;68:2039–51.

47. Hsieh M-F, Lai S-L, Chen J-P, Sung J-M, Lin Y-L, Wu-Hsieh BA, Gerard C, Kuznetsov VA, Schreiber M, Vasudevan SG, Hibbers ML. Host gene expression profiling of the immune response to Marburg virus infection. J Virol. 2015;89:9865–74.

48. Fadel SA, Bromley SK, Medoff BD, Luster AD. CXCRI deficiency protects influenza-infected CCR5-deficient mice from mortality. Eur J Immunol. 2008;38:3378–87.

49. Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, Luster AD. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol. 2002;168:3195–204.

50. Zeremski M, Petrovic JM, Chiriboga L, Brown QB, Yee HT, Kinkhabwala M, Jacobson IM, Dimova R, Markatou M, Talal AH. Intrahepatic levels of CXCRI-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology. 2008;48:1440–50.

51. Nakashima Y, Lu B, Gerard C, Ivasaki A, CD8(+)-T lymphocyte mobilization to virus-infected tissue requires CD4+ T-cell help. Nature. 2009;462:510–3.

52. Brainard DM, Tager AM, Misri J, Frahm N, Lichterfeld M, Draenert R, Brander C, Walker BD, Luster AD. Decreased CXCR3+ CD8 T cells in advanced human immunodeficiency virus infection suggest that a homing defect contributes to cytotoxic T-lymphocyte dysfunction. J Virol. 2007;81:8439–50.

53. Geisbert TW, Daddario-Dicaprio KM, Geisbert JB, Reed DS, Feldmann F, Grolla A, Ströher U, Fritz EA, Hensley LE, Jones SM, Feldmann H. Vescicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine. 2008;26:6894–900.